Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia

BACKGROUND: The paliperidone palmitate 6-month (PP6M) long-acting injectable formulation is currently the longest dosing interval available for schizophrenia treatment. OBJECTIVE: To compare treatment outcomes between a real-world external comparator arm (ECA; NeuroBlu database) and the PP6M open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Turkoz, Ibrahim, Wong, Joshua, Chee, Benjamin, Siddiqui, Uzma, Knight, R. Karl, Richarz, Ute, Correll, Christoph U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Long-Acting Antipsychotic Treatments
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541743/
https://www.ncbi.nlm.nih.gov/pubmed/37786804
http://dx.doi.org/10.1177/20451253231200258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541743/
https://www.ncbi.nlm.nih.gov/pubmed/37786804
http://dx.doi.org/10.1177/20451253231200258

Ejemplares similares